Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 12, 2025
– Strategic transformation to innovative oncology completed in Q2 2025 –
– Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting –
– Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing –
